This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Boehringer's diabetes drug patent revoked by JPO, appeal pending at Japan's IP High Court

By Toko Sekiguchi ( July 3, 2025, 07:51 GMT | Insight) -- The Japan Patent Office has invalidated a key Boehringer Ingelheim patent covering the dosage use of its DPP-IV inhibitor linagliptin for type 2 diabetes, siding with arguments from generics manufacturers that the claimed 5mg once-daily oral dosage was obvious. The ruling against the German pharmaceutical company has been appealed and is now under review at the Intellectual Property High Court in Japan.The Japan Patent Office, or JPO, has invalidated a key Boehringer Ingelheim patent covering the dosage use of its DPP-IV inhibitor linagliptin for type 2 diabetes, siding with arguments from generics manufacturers that the claimed 5mg once-daily oral dosage was obvious....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections